Introduction {#Sec1}
============

Biologicals including cytokines, monoclonal antibodies (mAbs), and fusion proteins are new therapeutic agents. In 1984, the Nobel prize was awarded to the scientists who discovered the mAbs \[[@CR1]\]. Today, over 150 biological agents have been approved for different types of cancers including lymphoma, leukemia, colorectal, breast, gastric and lung cancer, rheumatological diseases, and certain allergic and chronic inflammatory diseases, e.g., inflammatory bowel diseases, multiple sclerosis, and psoriasis \[[@CR2], [@CR3]\].

Nomenclature of biologic agents is based on rules. The first syllable of a biological is chosen randomly. The last syllable refers the mechanism of action: "-mab" for monoclonal antibody, "-cept" for soluble fusion receptors to Fc part of human immunoglobulin G1 (IgG1), and "-inib" for receptor antagonists. The penultimate syllable stands for the spices of origin: "-xi" indicates chimeric murine-human origin, "-zu" indicates humanized origin which contains complementarity determining regions of a mouse Ig onto human IgG1, and "-u" indicates fully human origin including human origin constant and variable regions. For monoclonal antibodies, the previous syllable indicates the target structure or target disease: "-li" for immune system, "-ta" for tumor, "-ci" for cardiovascular system, "-vi" for virus, and "-ki" for interleukin \[[@CR4], [@CR5]\]. For example, "omalizumab" refers to an immune system targeted, humanized monoclonal antibody or "etanercept" refers to a soluble receptor fusion protein.

Targeted activity of biological agents has made them more effective and less toxic treatment options. In 2006, they became more commonly used agents than cytotoxic therapies \[[@CR4]\]. As a result of increased use of biologics, various adverse effects have been observed \[[@CR6]\]. These include infusion-related reactions, cytokine release syndrome, hypersensitivity (immediate and delayed) reactions, immunodeficiency, autoimmunity, allergic/atopic disorders, cross-reactivity with normal cells (e.g., acne from antiepidermal growth factor receptor), and nonimmunological side effects (e.g., depression from interferons) \[[@CR7]\]. Immediate onset hypersensitivity reactions with monoclonal antibodies will be discussed in this article.

Clinical presentations {#Sec2}
======================

Hypersensitivity reactions (HSRs) are classified according to time of onset as immediate (\< 1 h of drug administration) or delayed (1 h to 1 week after drug administration) and to the mechanism involved: allergic or non-allergic \[[@CR8]\]. Delayed-type HSRs to biologics including rash, vasculitis, serum sickness like symptoms, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported \[[@CR9]--[@CR11]\]. Immediate onset HSRs include acute infusion--related reactions, cytokine release syndrome (CRS), and IgE-mediated hypersensitivity reactions. They may be clinically indistinguishable from each other, and mixed-type reactions may be observed.

Acute infusion--related reactions {#Sec3}
---------------------------------

Acute infusion--related reactions and CRS can occur at first administration with common clinical features such as fever, pruritus, flushing, tachycardia, hypertension, dyspnea, nausea, vomiting, and syncope. On the other hand, IgE-mediated reactions require repeated exposure to the antigen \[[@CR8], [@CR12]••, [@CR13]•\]. The most common HSR due to a monoclonal antibody is an acute infusion--related reaction; nevertheless, the underlying mechanism of these reactions is currently unknown. In addition to common symptoms, patients may display atypical clinical features such as rigor, back pain, and abdominal pain. Mild-to-moderate infusion reactions can be managed by premedication with corticosteroids, antihistamines and antipyretics, and slowing infusion rate \[[@CR14]•, [@CR15]\].

Cytokine release syndrome {#Sec4}
-------------------------

Cytokine release syndrome is a disorder characterized by nausea, headache, tachycardia, hypotension/hypertension, rash, and/or hypoxia. CRS is caused by the release of cytokines especially TNF-α, interferon-γ, and interleukin-6 from monocyte**s**, macrophages, cytotoxic T cells, and NK cells \[[@CR16], [@CR17]\]. Not only monoclonal antibodies but also non-protein-based cancer drugs, stem cell transplantation, graft-versus-host disease, and severe viral infections can cause CRS. The manifestation of CRS varies from flu-like symptoms to severe life-threatening conditions such as renal failure, cardiac dysfunction, and capillary leakage with pulmonary edema. In some cases, death has been reported. The respiratory system is commonly affected, and the manifestations vary from cough and tachypnea to acute respiratory distress syndrome depending on the severity of reaction \[[@CR18], [@CR19]\]. Treatment of CRS depends on the severity of the reaction. For mild and moderate reactions, management includes slowing the infusion rate (after a temporary break) and premedication with corticosteroids and acetaminophen. Severe reactions are usually clinically indistinguishable from IgE-mediated reactions, and management is similar to anaphylaxis \[[@CR13]•\].

IgE-mediated hypersensitivity reactions {#Sec5}
---------------------------------------

IgE-mediated hypersensitivity reactions occur as a result of basophil and mast cell activation. The binding of antigen-specific IgE to FcεRI receptor on the surface of basophils and mast cells leads to the release of mediators such as histamine, platelet-activating factor, cysteinyl leukotrienes, tryptase, and prostaglandins. Systemic effects of the mediators are responsible for clinical findings, cutaneous flushing, headache, airway obstruction, and hypotension. In addition, elevated serum levels of these mediators, especially tryptase, are helpful for the differential diagnosis of IgE-mediated reactions \[[@CR20]\]. The most severe form of IgE-mediated hypersensitivity is anaphylaxis, defined as severe life-threatening systemic hypersensitivity reactions. The clinical manifestations depend on the organ system involved: cutaneous, respiratory, gastrointestinal, or cardiovascular system \[[@CR21]\].

Up to now, more than 400 anaphylaxis cases induced by biological agents, including mAbs, cytokines, and enzymes, have been reported \[[@CR22]\]. Commonly, IgE-mediated reactions to drugs occur after a sensitization phase with multiple exposures to the drug~~s~~. A few exceptions have been reported on anaphylaxis during first administration of mAbs. Preexisting IgE antibodies against galactose-*α*-1,3-galactose (alpha-gal) have been identified as the underlying cause of first-dose anaphylaxis for cetuximab and infliximab. Alpha-gal is an oligosaccharide which is found in mammalian meats and Fc fragment and Fab portion of cetuximab heavy chain, Fc fragment of infliximab, and a few other monoclonal antibodies. Lone star tick (*Amblyomma americanum*) bitten patients develop IgE antibodies to alpha-gal. Therefore, first dose of cetuximab or infliximab may cause anaphylaxis \[[@CR23], [@CR24]\]. Bueren et al. showed that only alpha-gal present on the Fab domain of cetuximab binds to alpha-gal-specific IgE antibodies of sensitized patients in vitro and no binding to alpha-gal-specific IgE of other alpha-gal containing monoclonal antibodies, basiliximab, palivizumab, zalutumumab, panitumumab, and abatacept or the Fc fragment of cetuximab \[[@CR25]\]. However, theoretically~~,~~ patients sensitized to alpha-gal may experience anaphylaxis to the first dose of biologics which have alpha-gal motif in Fc fragments. Two cases of anaphylactic reactions during the first dose of basiliximab have been reported, but their alpha-gal IgE levels were unavailable \[[@CR26]\]. In addition to that, first-dose anaphylaxis to omalizumab has been reported due to polysorbate which is a solubilizing agent used in drugs to stabilize emulsions \[[@CR27], [@CR28]\]. Other additives of biological agents such as mannitol, albumin, polysorbate 80, latex, papain, and trometamol may have antigenic potential \[[@CR29]\].

Management {#Sec6}
----------

Emergency management of anaphylactic reactions to monoclonal antibodies is the same as in anaphylaxis from other causes. After evaluation of the airway, breathing, circulation, and removal of the allergen, which means immediate cessation of the infusion, first-line treatment is intramuscular administration of adrenaline. If the patient has no response to adrenaline within 5--10 min, intramuscular adrenaline should be repeated. Second-line and third-line treatments consist of oxygen, adequate position, nebulized adrenaline, nebulized beta-2-agonist, intravenous normal saline, corticosteroid, and antihistamine administration depending on the clinical presentation~~s~~ of the patient \[[@CR6], [@CR21]\]. Serum tryptase levels should be obtained 30--120 min after the reaction to differentiate anaphylaxis from infusion-related reactions and cytokine release syndrome. The severity of organ involvement such as cardiovascular symptoms is correlated with higher serum tryptase levels. Although elevated serum tryptase levels from baseline suggest mast cell activation, in some cases of anaphylaxis, serum tryptase levels may be within the normal range \[[@CR30], [@CR31]\].

If the patient has experienced anaphylaxis to monoclonal antibodies, skin tests with the culprit agent should be performed 4--6 weeks after the reaction. Timing is critical because mast cells are temporarily unresponsive to the allergen in skin tests for the period of 4 weeks. Although skin tests are the most sensitive and specific in vivo tests, no available standardized protocols have been defined for biological agents except adalimumab, etanercept, infliximab, and omalizumab \[[@CR32]\]. Furthermore, different skin testing concentrations for these mAbs and abatacept, bevacizumab, brentuximab, cetuximab, natalizumab, pertuzumab, rituximab, tocilizumab, and trastuzumab have been published in case reports (Table [1](#Tab1){ref-type="table"}) \[[@CR15], [@CR33]--[@CR41]\].Table 1Suggested skin testing concentrations for mAbsSPT (mg/mL)IDT (mg/mL)IDT (mg/mL)IDT (mg/mL)Abatacept \[[@CR14]•\]250.0250.252.5Adalimumab \[[@CR32]\]400.040.44Bevacizumab \[[@CR33]\]252.525--Brentuximab \[[@CR34]\]NA0.0050.05--Cetuximab \[[@CR33]\]50.55--Etanercept \[[@CR32], [@CR35]\]500.050.55Infliximab \[[@CR36]\]100.11--Omalizumab \[[@CR37]\]1250.001250.0125--Pertuzumab \[[@CR38]\]1.60.0160.16--Rituximab \[[@CR8]\]100.010.11Tocilizumab \[[@CR39]\]200.2220Trastuzumab \[[@CR8]\]210.212.121

If the clinical features do not strongly suggest an IgE-mediated reaction, serum tryptase level after 60 min of the reaction is within normal range, and SPTs with culprit drug are negative, the patient may receive the drug with graded challenge doses. Graded challenge should be performed with 1/10th of the total drug dose for initial administration. Also, starting with 1/100th of the total dose has been reported as an additional step before 1/10th of the therapeutic dose. If the patient tolerates initial doses, the rest of the drug could be given after a 30-min interval \[[@CR8], [@CR42]\]. Otherwise**,** desensitization with the culprit drug should be considered (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1The algorithm for management of hypersensitivity reactions with biologics.

Desensitization {#Sec7}
---------------

Desensitization of a drug defines temporary clinical tolerance to the culprit drug**.** First drug desensitizations have been performed for penicillin allergy \[[@CR43]\]. So far, antibiotics, aspirin, insulin, local anesthetics, chemotherapeutics, and biologic agents have been successfully administered with desensitization protocols \[[@CR44], [@CR45]\]. If the drug is unequal or more effective and/or less toxic than alternatives or has a unique mechanism of action, desensitization is indicated for patients who have experienced type 1 or type 4 reactions (except severe cutaneous adverse reactions). Type 2 reactions (immunocytotoxic reactions), vasculitis, type 3 reactions (serum sickness-like syndrome), and severe cutaneous adverse reactions (SJS/TEN, drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP)) are absolute contraindications for desensitization \[[@CR46]\]. For patients who have severe respiratory, cardiac, or systemic disease and experienced severe anaphylaxis (requiring intubation), desensitization should be considered after careful assessment of the risks and benefits. Also, patients taking beta-blockers or ACE inhibitors have an increased risk of severe reactions during desensitization \[[@CR47]\].

Various successful desensitization protocols of biologic agents have been published. A commonly applied desensitization protocol for mAbs is a 12-step/3-bag protocol which has been administrated previously for beta-lactam antibiotics and chemotherapeutic agents \[[@CR48], [@CR49]\]. Based on the risk of reaction, 4 to 16 steps could be administered with 2 or 4 bags \[[@CR12]••\]. For 3-bag protocol, the first bag has a 1/100 concentration, and the second bag has a 1/10 dilution of the routinely recommended drug concentration. The third step's dilution is obtained by subtracting the cumulative dose given at the first eight steps from the total target dose. Each step is administered by increasing infusion rate 2--2.5-fold doses of the previous step with 15-min intervals. The last step extends until the complete targeted dose is administered \[[@CR39]\]. An example of 3-bag/15-step modified desensitization protocol for tocilizumab is shown Table [2](#Tab2){ref-type="table"} \[[@CR50]\].Table 2Protocol for tocilizumab desensitizationStepSolutionTime (min)Total infusion timeVolume infused per step (mL)Dose administered/min (mg/min)Dose administered/step (mg)Cumulative dose (mg)1115150.60.00040.0060.0062115301.20.00080.0120.0183115452.40.00160.0240.0424115604.80.00320.0480.0952157510.00640.0960.18662159020.01280.1920.378721510540.02560.3840.76282151204.50.030.451.212921513560.040.61.8121021515090.060.92.71211215165120.081.23.91212215180150.11.55.41213215195300.238.41214215210450.34.512.91534756852000.4190200Solution 1 = 1 mg tocilizumab + 100 mL serum physiologic (0.01 mg/mL). Solution 2 = 10 mg tocilizumab + 100 mL serum physiologic (0.1 mg/mL). Solution 3 = 190 mg tocilizumab + 200 mL serum physiologic (0.95 mg/mL)

Desensitization protocols are available not only for intravenously administered agents but also for subcutaneously and orally administered biologic agents. A desensitization protocol of dasatinib, an orally administrated tyrosine kinase inhibitor, has been reported recently for delayed-type hypersensitivity reactions \[[@CR51]\]. For adalimumab and etanercept, which are subcutaneously administered monoclonal antibodies, six or seven-step desensitization protocols have been defined. The initial dose is administrated as 1 mL of 1/100 dilution of the routinely administrated concentration, and the next doses increase at each step as 0.5--2-fold doses of the previous one with 30-min intervals \[[@CR36], [@CR52]\].

Brennan et al. have applied 105 desensitizations with trastuzumab, infliximab, and rituximab in 23 adult patients with rheumatologic diseases or malignancy. One hundred and four out of 105 desensitizations were successfully completed. HSR were reported in 29% of the desensitizations, and a majority of them were mild \[[@CR39]\]. Isabwe et al. have published recently the largest report of desensitization series (*n* = 526) for mAbs with 16 different agents, including rituximab, infliximab, tocilizumab, brentuximab, trastuzumab, obinutuzumab, abatacept, ofatumumab, bevacizumab, pertuzumab, omalizumab, adalimumab, nivolumab, pembrolizumab, golimumab, and cetuximab. For intravenous mAbs, a 4--16-step/3-bag protocol is used; for subcutaneous mAbs, a 7-step protocol was used in 104 adult patients. In 23% of desensitizations, mild to severe hypersensitivity reactions were observed. The majority of reactions were mild and occurred during the last step of the protocol, and only one patient received adrenaline \[[@CR12]••\]. Besides, rituximab and tocilizumab desensitizations have been performed in pediatric patients. Five children who had anaphylaxis during rituximab or tocilizumab infusion underwent 84 desensitizations. Hypersensitivity was reported during only two out of 84 desensitizations, and one of them required adrenaline administration \[[@CR50]\]. In addition to previously described mAbs, successful desensitizations have been reported for alemtuzumab, denosumab, eculizumab, and natalizumab \[[@CR53]--[@CR57]\].

Premedication {#Sec8}
-------------

H1 and H2 antihistamines (diphenhydramine/hydroxyzine/cetirizine and famotidine/ranitidine) are routinely administered 20 min before the initiation of all protocols. Second generation antihistamines which have longer half-lives can be given since reactions during desensitization usually occur in the last two steps \[[@CR42], [@CR58]\]. Based on the severity and clinical findings of the initial reaction, additional drugs may be administered before the initiation of desensitization. Acetaminophen, nonsteroidal antiinflammatory drugs, and corticosteroids can be used to avoid fever and pain. Patients who experienced bronchospasm can take montelukast and corticosteroids. Also, montelukast and aspirin can be administered to prevent flushing. Low-dose benzodiazepines may be useful to treat anxiety during the desensitization \[[@CR12]••, [@CR39], [@CR58]\].

The reactions occurring during the desensitization can be treated with antihistamines, corticosteroids, and acetaminophen depending on the symptoms. Slowing down the infusion rate or an additional dose of antihistamine at the beginning of the previous step of the one where the reaction occurred should be performed at the following desensitizations. In spite of these procedures, if a reaction occurs during the desensitization, reducing the total targeted dose might be considered \[[@CR12]••, [@CR13]•\]. Also, prophylactic normal saline infusion (100 cc/h along the first 11 steps and 250 cc/h along the last step) can be used to prevent cytokine release syndrome during the desensitization \[[@CR12]••\].

Risk factors and prevention {#Sec9}
---------------------------

Monoclonal antibodies have the potential to stimulate immune responses due to their high molecular weight, presence of murine epitopes (chimeric mAbs), or conformationally changed neoepitopes (humanized mAbs) \[[@CR14]•\]. Although humanization of mAbs reduces the potential of immunogenicity, generalized urticaria and anaphylaxis have been reported with the fully human mAbs canakinumab and adalimumab, respectively \[[@CR59], [@CR60]\].

The underlying disease is an important factor for developing HSRs. Antirituximab antibodies develop more frequently in patients with systemic lupus erythematosus than in those with lymphoma \[[@CR15]\]. In addition to that, it was shown that infliximab-related reaction rate is higher in patients who have rheumatoid arthritis than in patients who have seronegative spondyloarthritis and vasculitis \[[@CR61]\]. These observations can suggest that patients suffering from an autoimmune disease may have an increased risk of HSR. Recently, Soyer et al. showed that renal involvement, frequent hospitalization, and exposure to more than two different biologic agents are risk factors for HSRs in children with rheumatologic diseases \[[@CR59]\].

Antidrug antibodies (ADAs) are associated with immediate HSRs. Development of ADA to infliximab is associated with concomitant treatment with immunosuppressive agents and administration intervals. Patients who take immunosuppressors have lower incidence of ADA to infliximab, and longer intervals between infliximab administrations increase the risk of developing ADA \[[@CR62]\]. Therefore, regular infusion regimens should be preferred to reduce HSRs to infliximab \[[@CR15]\]. Also, cross-reactivity between TNF-α inhibitors is not common, so if the patient has hypersensitivity to infliximab, other TNF-α inhibitors such as etanercept or adalimumab may be safe alternative treatment options \[[@CR31]\].

Conclusions {#Sec10}
===========

As a result of antibody engineering technologies, biologic agents have become more widely used therapeutic agents for rheumatologic diseases, cancers, and other chronic inflammatory diseases. Their complex structures and content of variable amounts of foreign regions may lead to HSRs. Although anaphylaxis is not the most common form of HSR, it may limit the clinical usage of biologic agents. Acute management of anaphylaxis to biologics is similar to that applied to other causes of anaphylaxis, but subsequent administration of the drug remains as a problem to be solved. If the drug is first-line treatment option or more effective than other drugs, desensitization can be performed under supervision of an experienced allergist. Nevertheless, further research is needed to understand the underlying mechanisms of hypersensitivity reactions to increase safety and efficacy of biologics.
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